Xiamen Amoytop Biotech Co Ltd
SSE:688278
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Xiamen Amoytop Biotech Co Ltd
Accounts Payable
Xiamen Amoytop Biotech Co Ltd
Accounts Payable Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Accounts Payable | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
X
|
Xiamen Amoytop Biotech Co Ltd
SSE:688278
|
Accounts Payable
¥106.5m
|
CAGR 3-Years
3%
|
CAGR 5-Years
41%
|
CAGR 10-Years
N/A
|
|
|
Beigene Ltd
HKEX:6160
|
Accounts Payable
¥4.4B
|
CAGR 3-Years
19%
|
CAGR 5-Years
34%
|
CAGR 10-Years
N/A
|
|
|
Innovent Biologics Inc
HKEX:1801
|
Accounts Payable
¥494.6m
|
CAGR 3-Years
15%
|
CAGR 5-Years
33%
|
CAGR 10-Years
N/A
|
|
|
RemeGen Co Ltd
SSE:688331
|
Accounts Payable
¥285.9m
|
CAGR 3-Years
38%
|
CAGR 5-Years
35%
|
CAGR 10-Years
N/A
|
|
|
Akeso Inc
HKEX:9926
|
Accounts Payable
¥451.8m
|
CAGR 3-Years
14%
|
CAGR 5-Years
32%
|
CAGR 10-Years
N/A
|
|
|
S
|
Sichuan Kelun-Biotech Biopharmaceutical Co Ltd
HKEX:6990
|
Accounts Payable
¥383m
|
CAGR 3-Years
36%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Xiamen Amoytop Biotech Co Ltd
Glance View
Xiamen Amoytop Biotech Co., Ltd., nestled in the heart of China's coastal city Xiamen, unfolds its narrative as a dynamic player in the biotechnology and healthcare industries. Born from an environment brimming with innovation, the company has diligently carved its niche by focusing on the research, development, and commercialization of diagnostic reagents and test kits. Its core competency lies in crafting solutions designed for precision and reliability, addressing the ever-evolving needs of laboratories and healthcare providers. Through a blend of cutting-edge technology and a keen understanding of biological complexities, Xiamen Amoytop has established itself as a reliable partner, providing essential tools that drive accurate diagnostics and improve patient outcomes across the globe. The company generates revenue by designing and delivering an extensive array of diagnostic products that are indispensable to modern medical practices. From infectious disease diagnostics to blood-based tests, Xiamen Amoytop leverages advancements in molecular biology to offer products that elevate the standards of health diagnostics. By supplying these critical products, the company ensures a steady flow of income sourced from healthcare facilities, research institutions, and diagnostic laboratories both domestically and internationally. Through its robust distribution network and focus on quality assurance, the company continues to expand its market presence, translating its technological prowess into financial growth and global impact.
See Also
What is Xiamen Amoytop Biotech Co Ltd's Accounts Payable?
Accounts Payable
106.5m
CNY
Based on the financial report for Dec 31, 2025, Xiamen Amoytop Biotech Co Ltd's Accounts Payable amounts to 106.5m CNY.
What is Xiamen Amoytop Biotech Co Ltd's Accounts Payable growth rate?
Accounts Payable CAGR 5Y
41%
Over the last year, the Accounts Payable growth was 77%. The average annual Accounts Payable growth rates for Xiamen Amoytop Biotech Co Ltd have been 3% over the past three years , 41% over the past five years .